All In MedTech

Device Trial Radar · NCT06310031

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

Investigation of a Novel, magNetically Levitated VAD for the Treatment of refractOry Left Ventricular heArT failurE

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 780 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

780

Planned (sponsor's estimate)

Start

Oct 28, 2024

Primary completion

Feb 2028

Study completion Dec 2028

Sponsor

Lead sponsor
BrioHealth Solutions, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 13, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

Conditions

  • Cardiovascular Diseases
  • Heart Diseases
  • Heart Failure

Interventions

  • BrioVAD SystemDevice

    Implantation of the BrioVAD System to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.

  • HeartMate 3Device

    Implantation of the commercially approved HeartMate 3 LVAS, which is the standard treatment for advanced heart failure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Short-Term Indication Primary EndpointTime frame: 6 months
  2. Long-Term Indication Primary EndpointTime frame: 24 months

Locations

47 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Hospital

    Birmingham, Alabama

  • Baptist Health Medical Center-Little Rock

    Little Rock, Arkansas

  • Cedars-Sinai Medical Center

    Los Angeles, California

44 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.